Jpmorgan Chase & CO Opti Nose, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding OPTN
# of Institutions
62Shares Held
88.3MCall Options Held
0Put Options Held
0-
Mvm Partners, LLC Boston, MA14.6MShares$6.13 Million10.4% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT14.4MShares$6.03 Million0.57% of portfolio
-
Great Point Partners LLC Greenwich, CT12.9MShares$5.4 Million3.98% of portfolio
-
Stonepine Capital Management, LLC Bend, OR5.69MShares$2.39 Million2.41% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY5.6MShares$2.35 Million0.45% of portfolio
About OptiNose, Inc.
- Ticker OPTN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 83,277,504
- Market Cap $35M
- Description
- OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...